SAM
ARQT icon

Sectoral Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Sectoral Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,357
Closed -$23.1K – 105
2023
Q3 		$23.1K Sell
4,357
-9,930
-70% -$84.4K ﹤0.01% 123
2023
Q2 		$136K Sell
14,287
-302,865
-95% -$3.36M 0.02% 120
2023
Q1 		$3.49M Buy
317,152
+113,300
+56% +$1.64M 0.67% 61
2022
Q4 		$3.02M Sell
203,852
-17,133
-8% -$299K 0.58% 69
2022
Q3 		$4.22M Buy
220,985
+40,969
+23% +$928K 0.83% 54
2022
Q2 		$3.84M Sell
180,016
-39,120
-18% -$802K 0.77% 56
2022
Q1 		$4.22M Sell
219,136
-24,600
-10% -$416K 0.75% 53
2021
Q4 		$5.05M Sell
243,736
-515,027
-68% -$10.3M 0.76% 52
2021
Q3 		$18.1M Hold
758,763
– – 1.51% 20
2021
Q2 		$20.7M Sell
758,763
-120,185
-14% -$3.39M 1.68% 15
2021
Q1 		$25.4M Buy
+878,948
New +$27.4M 1.93% 10

Other funds holding ARQT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Sectoral Asset Management's ARQT Position: Q4 2023 in Review

Sectoral Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 4,357 shares — an estimated $23.1K sold.

Sectoral Asset Management first reported a position in ARQT in Q1 2021 and held it in 11 quarters. The position peaked at $25.4M in Q1 2021. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

  • Sectoral Asset Management reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Sectoral Asset Management sold 4,357 Arcutis Biotherapeutics shares in Q4 2023, an estimated $23.1K.
  • Sectoral Asset Management first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 11 quarters.
  • Sectoral Asset Management's Arcutis Biotherapeutics position peaked at $25.4M in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on Sectoral Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.